Sensei continues to advance SNS-101 through investigational new drug-enabling studies, and intends to submit an Investigational New Drug application in or prior to April 2023. The Company has reported differentiated preclinical data demonstrating anti-tumor effects, promising pharmacokinetic properties and a superior cytokine release profile compared with non-conditional anti-VISTA therapies. While it advances SNS-101 into the clinic in the near-term, Sensei will continue discovery work for its discovery-stage programs targeting VSIG-4 and ENTPDase1, also known as CD39.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on SNSE:
- Sensei Biotherapeutics Provides Update on Strategic Priorities
- Sensei Biotherapeutics management to meet virtually with Oppenheimer
- Sensei Biotherapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference
- Sensei Biotherapeutics Announces Collaboration with Washington University, St. Louis to Support Development of SNS-101, a Conditionally Active VISTA-blocking Antibody
- Sensei Biotherapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights
